Company intelligence / Profile preview

Tonghua Maoxiang Pharmaceutical

Tonghua, Jilin, China

Ownership: Private
Development stage: Other

Overview

Tonghua Maoxiang Pharmaceutical is a private Chinese pharmaceutical company focusing primarily on small molecule drugs for oncology. Its main commercial assets include chloroquine (chloroxoquinoline) capsules, which have completed Phase 4 evaluation for safety and efficacy in breast cancer and non-small cell lung cancer. The company has also conducted comparative bioequivalence and safety studies for methotrexate tablets.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Tonghua Maoxiang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tonghua Maoxiang Pharmaceutical.

Explore the full profile